Certolizumab pegol therapy of rheumatoid arthritis: Overview

Drug Development Research

Volumn 72, Issue 7, 2011, Pages 603-614

  Zidi, Ines ^a,b   Mnif, Wissem ^a   Bouaziz, Aicha ^a,c   Amor, Nidhal Ben ^a,b  

^a UNIVERSITY OF MONASTIR   (Tunisia)

^b KING FAISAL UNIVERSITY   (Saudi Arabia)

^c Laboratory of Basic Health Group   (Tunisia)

Author keywords

autoimmune disease; Certolizumab pegol; inhibitors; rheumatoid arthritis; TNF

Indexed keywords

ADALIMUMAB; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CERTOLIZUMAB PEGOL; CREATININE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; LIVER ENZYME; MACROGOL; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA; UREA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL ARTHRITIS; BACTERIAL INFECTION; BACTERIURIA; BLADDER CANCER; BRAIN ISCHEMIA; COLON CANCER; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; HEADACHE; HEMATURIA; HERPES SIMPLEX; HODGKIN DISEASE; HUMAN; HYPERTENSION; INJECTION SITE PAIN; INJECTION SITE REACTION; LIVER CANCER; LOWER RESPIRATORY TRACT INFECTION; MENORRHAGIA; MYCOSIS; NECK PAIN; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SEPSIS; SIDE EFFECT; TESTIS CANCER; THYROID TUMOR; TREATMENT RESPONSE; TUBERCULOSIS; UREA BLOOD LEVEL; URINARY TRACT INFECTION; UTERUS MYOMA; VIRUS INFECTION;

EID: 82155191397     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20470     Document Type: Review

References (64)

1. Alexis F, Pridgen E, Molnar LK, Farokhzad OC,. 2008. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 5: 505-515.
2. Atzeni F, Sarzi-Puttini P, Gorla R, Marchesoni A, Caporali R,. 2011. Switching rheumatoid arthritis treatments: an update. Autoimmun Rev 10: 397-403.
3. Barnes T, Moots R,. 2007. Targeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegol. Int J Nanomed 2: 3-7. (Pubitemid 46901774)
4. Bendele A, Seely J, Richey C, Sennello G, Shopp G,. 1998. Renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins. Toxicol Sci 42: 152-157. (Pubitemid 28211143)
5. Bingham CO,. 2008. Emerging therapeutics for rheumatoid arthritis. Bull NYU Hosp Jt Dis 66: 210-215.
6. Boissier MC, Assier E, Denys A,. 2010. Les cibles thérapeutiques des rhumatismes inflammatoires. In:, Boissier MC, editor. Biothérapies en rhumatologie. Paris: Springer-Verlag. p 7-19.
7. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M,. 1989. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2: 244-247. (Pubitemid 19180612)
8. Bugatti S, Codullo V, Caporali R, Montecucco C,. 2007. B cells in rheumatoid arthritis. Autoimmun Rev 7: 137-142. (Pubitemid 350116726)
9. Chames P, Van Regenmortel M, Weiss E, Baty D,. 2009. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol 157: 220-233.
10. Choy EH, Hazleman B, Smith M, Moss K, Lisi L, Scott DG, Patel J, Sopwith M, Isenberg DA,. 2002. Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxf) 41: 1133-1137. (Pubitemid 35203540)
11. Constantinou A, Chen C, Deonarain MP,. 2010. Modulating the pharmacokinetics of therapeutic antibodies. Biotechnol Lett 32: 609-622.
12. Deighton C,. 2010. If it works why can't we have it? Sequential anti-TNF therapy in the UK. Rheumatology (Oxf) 49: 2235-2236.
13. Ding T, Ledingham J, Luqmani R, Westlake S, Hyrich K, Lunt M, Kiely P, Bukhari M, Abernethy R, Bosworth A, et al., Standards AaGWGoBCAC, BHPR. 2010. BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology (Oxf) 49: 2217-2219.
14. Ehlers MR, Leary ET,. 2008. Biochemical markers of rheumatoid arthritis and osteoarthritis: clinical utility and practical considerations. In:, Reid DM, Miller CG, editors. Clinical trials in rheumatoid arthritis and osteoarthritis. London, UK: Springer-Verlag. p 151-169.
15. Elbakri A, Nelson PN, Abu Odeh RO,. 2010. The state of antibody therapy. Hum Immunol 71: 1243-1250.
16. Fishburn CS,. 2008. The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. J Pharm Sci 97: 4167-4183.
17. Fleischmann R, Vencovsky J, van Vollenhoven RF, Borenstein D, Box J, Coteur G, Goel N, Brezinschek HP, Innes A, Strand V,. 2009. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis 68: 805-811.
18. Food and Drug Administration. 2009. FDA labeling information. FDA web site on line <>.
19. Fossati G, Nesbitt A,. 2011a. Certolizumab Pegol has a different profile from other anti-TNFs, including Golimumab, in a variety of in vitro assays. Ann Rheum Dis 70: A1-A94.
20. Fossati G, Nesbitt A,. 2011b. Effect of the PEG component of Certolizumab pegol on calcium flux in cellular systems. Ann Rheum Dis 70: A1-A94.
21. Furst DE, Fleischmann R, Kopp E, Schiff M, Edwards CR, Solinger A, Macri M, Group S,. 2005. A phase 2 dose-finding study of PEGylated recombinant methionyl human soluble tumor necrosis factor type I in patients with rheumatoid arthritis. J Rheumatol 32: 2303-2310. (Pubitemid 41780638)
22. Furst DE, Keystone EC, Braun J, Breedveld FC, Burmester GR, De Benedetti F, Dörner T, Emery P, Fleischmann R, Gibofsky A, et al. 2011. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. Ann Rheum Dis 70: i2-i36.
23. Harris J, Keane J,. 2010. How tumour necrosis factor blockers interfere with tuberculosis immunity. Clin Exp Immunol 161: 1-9.
24. Kaushik VV, Moots RJ,. 2005. CDP-870 (certolizumab) in rheumatoid arthritis. Expert Opin Biol Ther 5: 601-606. (Pubitemid 40593341)
25. Kavanaugh A, Smolen JS, Emery P, Purcaru O, Keystone E, Richard L, Strand V, van Vollenhoven RF,. 2009. Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis. Arthritis Rheum 61: 1592-1600.
26. Keystone E, Heijde D, Mason DJ, Landewé R, Vollenhoven RV, Combe B, Emery P, Strand V, Mease P, Desai C, Pavelka K,. 2008. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 58: 3319-3329.
27. Keystone EC,. 2009. Biologics: rapid control of symptoms in rheumatoid arthritis. In: Satellites: biologics and beyond: understanding and meeting the needs of people with rheumatoid arthritis. London, UK: BMJ. p 2-4.
28. Klippel JH, Stone JH, Crofford LJ, White PH,. 2010. Rheumatoid arthritis. In:, Klippel JH, Stone JH, Crofford LJ, White PH, editors. The pocket primer on the rheumatic diseases. London, UK: Springer-Verlag. p 59-66.
29. Lacroix BD, Lovern MR, Stockis A, Sargentini-Maier ML, Karlsson MO, Friberg LE,. 2009. A pharmacodynamic Markov mixed-effects model for determining the effect of exposure to certolizumab pegol on the ACR20 score in patients with rheumatoid arthritis. Clin Pharmacol Ther 86: 387-395.
30. Launois R, Avouac B, Berenbaum F, Blin O, Bru I, Fautrel B, Joubert JM, Sibilia J, Combe B,. 2011. Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian metaanalysis. J Rheumatol. 38: 835-845.
31. Lee DM, Weinblatt ME,. 2001. Rheumatoid arthritis. Lancet 358: 903-911. (Pubitemid 32900579)
32. Li SD, Huang L,. 2008. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm 5: 496-504.
33. Lu Y, Harding SE, Turner A, Smith B, Athwal DS, Grossmann JG, Davis KG, Rowe AJ,. 2008. Effect of PEGylation on the solution conformation of antibody fragments. J Pharm Sci 97: 2062-2079.
34. Maciejewska Rodrigues H, Jüngel A, Gay RE, Gay S,. 2009. Innate immunity, epigenetics and autoimmunity in rheumatoid arthritis. Mol Immunol 47: 12-18.
35. Massarotti EM,. 2009. FAST4WARD: implications for the clinician. Int J Clin Pract 63: 986-988.
36. Monfardini C, Veronese FM,. 1998. Stabilization of substances in circulation. Bioconjug Chem 9: 418-450. (Pubitemid 28338758)
37. Moots RJ,. 2009. Real life usage of biologics. In: Satellites: advances in the management of rheumatoid arthritis. Proceedings of two CPD-accredited satellite symposia supported by Wyeth at EULAR, 11 and 13 June 2008. London, UK: BMJ. p 22-25.
38. Nam JL, Winthrop KL, van Vollenhoven RF, Pavelka K, Valesini G, Hensor EM, Worthy G, Landew é R, Smolen JS, Emery P, Buch MH,. 2010. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 69: 976-986.
39. National Institute for Health and Clinical Excellence. 2010. TA186 Rheumatoid arthritis-certolizumab pegol: guidance. NICE web site on line <>.
40. Nesbitt A, Fossati G, Brown D, Henry A, Palframan R, Stephens S,. 2008. Differences in the function and mode of action of certolizumab pegol and conventional anti-TNFs. Ann Rheum Dis 67: A49.
41. O'Dell JR,. 2010. Pharmacotherapy: concepts of pathogenesis and emerging treatments. Challenges in clinical trial design in inflammatory arthritis. Best Pract Res Clin Rheumatol 24: 457-461.
42. Palframan R, Airey M, Moore A, Vugler A, Nesbitt A,. 2009. Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. J Immunol Methods 348: 36-41.
43. Papagoras C, Voulgari PV, Drosos AA,. 2010. Strategies after the failure of the first anti-tumor necrosis factor alpha agent in rheumatoid arthritis. Autoimmun Rev 9: 574-582.
44. Pincus T, Sokka T,. 2001. How can the risk of long-term consequences of rheumatoid arthritis be reduced? Best Pract Res Clin Rheumatol 15: 139-170. (Pubitemid 32396434)
45. Pisal DS, Kosloski MP, Balu-Iyer SV,. 2010. Delivery of therapeutic proteins. J Pharm Sci 99: 2557-2575.
46. Rovenský J, Pavelka K, Bauerová K, Kucharská J,. 2008. Rheumatoid arthritis. In:, Gvozdjáková A, editor. Mitochondrial medicine: mitochondrial metabolism, diseases, diagnosis and therapy. Springer-Verlag. p 201-246.
47. Russell AS, Olszynski WP, Davison KS, Koehn C, Haraoui B,. 2010. Leveling the field in the treatment of rheumatoid arthritis with biologic therapies: equal access for equal efficacy. Clin Rheumatol 29: 233-239.
48. Scott DL, Cope A,. 2009. New tumour necrosis factor inhibitors for rheumatoid arthritis: are there benefits from extending choice? Ann Rheum Dis 68: 767-769.
49. Scott DL, Kingsley GH,. 2007. Rheumatoid arthritis. In:, Scott DL, Kingsley GH, editors. Inflammatory arthritis in clinical practice. London, UK: Springer-Verlag. p 1-31.
50. Scott DL, Wolfe F, Huizinga TW,. 2010. Rheumatoid arthritis. Lancet 376: 1094-1108.
51. Senolt L, Vencovský J, Pavelka K, Ospelt C, Gay S,. 2009. Prospective new biological therapies for rheumatoid arthritis. Autoimmun Rev 9: 102-107.
52. Shealy DJ, Visvanathan S,. 2008. Anti-TNF Antibodies: lessons from the past, roadmap for the future. In:, Chernajovsky Y, Nissim A, editors. Therapeutic antibodies. Handbook of experimental pharmacology. Berlin: Springer-Verlag. p 101-130.
53. Singh SK,. 2011. Impact of product-related factors on immunogenicity of biotherapeutics. J Pharm Sci 100: 354-387.
54. Smolen J, Landew é RB, Mease P, Brzezicki J, Mason D, Luijtens K, van Vollenhoven RF, Kavanaugh A, Schiff M, Burmester GR, et al. 2009. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 68: 797-804.
55. Strand V, Mease P, Burmester GR, Nika ï E, Coteur G, van Vollenhoven R, Combe B, Keystone EC, Kavanaugh A,. 2009. Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial. Arthritis Res Ther 11: R170.
56. Taylor PC,. 2010. Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. Curr Opin Pharmacol 10: 308-315.
57. Tebib JG, Miossec P,. 2006. Management of the patient with rheumatoid arthritis. In:, Bouysset M, Tourné Y, Tillmann K, editors. Foot and ankle in rheumatoid arthritis. Paris: Springer-Verlag. p 97-109.
58. van Vollenhoven RF, Felson D, Strand V, Weinblatt ME, Luijtens K, Keystone E,. 2011. American College of Rheumatology hybrid analysis of certolizumab pegol plus methotrexate in patients with active rheumatoid arthritis: data from a 52-week phase III trial. Arthritis Care Res 63: 128-134.
59. Veronese FM, Pasut G,. 2008. PEGylation: posttranslational bioengineering of protein biotherapeutics. Drug Discov Today Technol 5: e57-e64.
60. Vlieghe P, Lisowski V, Martinez J, Khrestchatisky M,. 2010. Synthetic therapeutic peptides: science and market. Drug Discov Today 15: 40-56.
61. Wilke WS, Clough JD,. 1991. Therapy for rheumatoid arthritis: combinations of disease-modifying drugs and new paradigms of treatment. Semin Arthritis Rheum 21: 21-34.
62. Wordsworth P, Holden W,. 2005. Rheumatoid arthritis. In: eLS. John Wiley & Sons, Ltd: Chichester [ doi:10.1038/npg.els.0006101 ].
63. Yen JH,. 2006. Treatment of early rheumatoid arthritis in developing countries. Biologics or disease-modifying anti-rheumatic drugs? Biomed Pharmacother 60: 688-692.
64. Zidi I, Bouaziz A, Mnif W, Bartegi A, Al-Hizab FA, Amor NB,. 2010. Golimumab therapy of rheumatoid arthritis: an overview. Scand J Immunol 72: 75-85.